scholarly journals Medication Related Osteonecrosis of Jaw: A Medical Oncologist’s Perspective

2018 ◽  
Vol 1 (1) ◽  
pp. 10-17
Author(s):  
Harry S Darling
Keyword(s):  
Quality Of Life ◽  
Medical Oncology ◽  
Cancer Therapeutics ◽  
Therapeutic Action ◽  
Treatment Of Osteoporosis ◽  
Medical Oncologists ◽  
Osteonecrosis Of Jaw ◽  
High Index Of Suspicion ◽  
Major Emphasis

Medication related osteonecrosis of jaw (MRONJ) is a rare iatrogenic disease. Cancer therapeutics is advancing exponentially and apart from a major emphasis on quality of life (QoL) in metastatic patients, now we are foreseeing increased longevity. This necessitates the rising need of betterment of supportive care modalities and looking into the rare complications of therapy. Bisphosphonates (BPs) and Denosumab, the anti-resorptive agents (ARAs) used commonly by medical oncologists in cancers with bone metastases and less commonly in prevention or treatment of osteoporosis, are implicated in the etiology of MRONJ. Many a times, it goes undetected, underdiagnosed and untreated due to lack of awareness, low index of suspicion and paucity of understanding of this disorder amongst medical oncology fraternity. A high index of suspicion is a cornerstone of timely diagnosis and therapeutic action. A regular collaboration between treating oncologist and dentist is of utmost importance.

Sexuality and quality of life of the young woman with breast cancer in a Moroccan context: experience of the medical oncology department CHU Hassan II FEZ

The Breast ◽  
2017 ◽  
Vol 32 ◽  
pp. S86 ◽  
Author(s):  
H. Ouahbi ◽  
F.Z. El’emrabet ◽  
L. Amaadour ◽  
M. Benhami ◽  
O. Sy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Young Woman ◽  
Medical Oncology

Sleep Disturbance in Palliative Care

2018 ◽  
Author(s):  
Rebecca Burke ◽  
Sriram Yennurajalingam
Keyword(s):  
Quality Of Life ◽  
Palliative Care ◽  
Sleep Disturbance ◽  
Poor Sleep ◽  
Primary Care Population ◽  
Nonrestorative Sleep ◽  
Falling Asleep ◽  
High Index Of Suspicion ◽  
Prevalent Symptom

Sleep disturbance is a persistent source of suffering in palliative care patients. Symptoms such as difficulty falling asleep, staying asleep, early awakening, or nonrestorative sleep are all indicative of sleep disorders. Poor sleep can have consequential effects on perception of pain, fatigue, mood, and quality of life. It is not only a prevalent symptom in the primary care population but also may in fact affect more than 60% of the palliative care population. In addition to the complexities of treatment, insomnia often serves as a red herring to alarm physicians of underlying conditions. Therefore, it is essential that palliative care physicians maintain a high index of suspicion for such confounding conditions as restless leg syndrome, sleep apnea, and delirium. This chapter highlights the intricacies of sleep disturbance and focuses on the most common patient presentations.

scholarly journals An overview on the treatment of postmenopausal osteoporosis

2014 ◽  
Vol 58 (2) ◽  
pp. 162-171 ◽  
Author(s):  
Sergio Setsuo Maeda ◽  
Marise Lazaretti-Castro
Keyword(s):  
Quality Of Life ◽  
Vitamin D ◽  
Pharmacological Treatment ◽  
Bone Cells ◽  
Treatment Of Osteoporosis ◽  
Drug Intolerance ◽  
Active Medication ◽  
Novel Drugs ◽  
Substantial Morbidity

Osteoporosis is a worldwide health problem related to the aging of the population, and it is often underdiagnosed and undertreated. It is related to substantial morbidity, mortality and impairment of the quality of life. Estrogen deficiency is the major contributing factor to bone loss after menopause. The lifetime fracture risk at 50 years of age is about 50% in women. The aim of the treatment of osteoporosis is to prevent fractures. Non-pharmacological treatment involves a healthy diet, prevention of falls, and physical exercise programs. Pharmacological treatment includes calcium, vitamin D, and active medication for bone tissue such, as anti-resorptives (i.e., SERMs, hormonal replacement therapy, bisphosphonates, denosumab), bone formers (teriparatide), and mixed agents (strontium ranelate). Bisphosphonates (alendronate, risedronate, ibandronate, and zoledronate) are the most used anti-resorptive agents for the treatment of osteoporosis. Poor compliance, drug intolerance, and adverse effects can limit the benefits of the treatment. Based on the knowledge on bone cells signaling, novel drugs were developed and are being assessed in clinical trials.

scholarly journals Delayed diagnosis in metastatic lesions of the foot

2014 ◽  
Vol 96 (7) ◽  
pp. 536-538 ◽  
Author(s):  
S Evans ◽  
A Ramasamy ◽  
L Jeys ◽  
R Grimer
Keyword(s):  
Quality Of Life ◽  
Clinical Course ◽  
Rare Complication ◽  
Delayed Diagnosis ◽  
Foot Pain ◽  
Orthopaedic Oncology ◽  
Median Length ◽  
Metastatic Lesions ◽  
High Index Of Suspicion

Introduction Pedal acrometastases are a rare complication of disseminated malignancy. To date, there is little in the literature documenting their clinical course. Methods Our large orthopaedic oncology database was used to review the clinical course of symptomatic pedal acrometastases. Results A total of 15 cases of pedal acrometastases were identified from 2,595 patients with metastases. The median age at presentation was 64.5 years (range: 14–83 years) and the median length of foot symptoms (predominantly pain and swelling) prior to diagnosis of metastasis was 16 weeks (range: 6–104 weeks). The median survival following diagnosis was 4.6 months (range: 2.3–104.5 months). Conclusions This study suggests that 0.58% of all osseous metastases involve the foot, and that symptoms of foot pain and swelling are often misdiagnosed, leading to delays in treatment. A high index of suspicion is required to diagnose pedal acrometastases early, thereby allowing early treatment so that the patient’s quality of life can be maintained prior to death.

scholarly journals Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer

2014 ◽  
Vol 9 (1) ◽  
pp. 1-10 ◽  
Author(s):  
Desiree Jones ◽  
Fengmin Zhao ◽  
Joanna Brell ◽  
Mark A. Lewis ◽  
Charles L. Loprinzi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Patient Care ◽  
Medical Oncology

scholarly journals Creating a Blueprint of Well-Being in Oncology: An Approach for Addressing Burnout From ASCO’s Clinician Well-Being Taskforce

2021 ◽  
pp. e339-e353
Author(s):  
Fay J. Hlubocky ◽  
Tait D. Shanafelt ◽  
Anthony L. Back ◽  
Judith A. Paice ◽  
Eric D. Tetzlaff ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Task Force ◽  
Well Being ◽  
Care Patient ◽  
Direct Access ◽  
Personal Health ◽  
Medical Oncologists ◽  
Health Related ◽  
Integrative Concept

Optimizing the well-being of the oncology clinician has never been more important. Well-being is a critical priority for the cancer organization because burnout adversely impacts the quality of care, patient satisfaction, the workforce, and overall practice success. To date, 45% of U.S. ASCO member medical oncologists report experiencing burnout symptoms of emotional exhaustion and depersonalization. As the COVID-19 pandemic remains widespread with periods of outbreaks, recovery, and response with substantial personal and professional consequences for the clinician, it is imperative that the oncologist, team, and organization gain direct access to resources addressing burnout. In response, the Clinician Well-Being Task Force was created to improve the quality, safety, and value of cancer care by enhancing oncology clinician well-being and practice sustainability. Well-being is an integrative concept that characterizes quality of life and encompasses an individual's work- and personal health–related environmental, organizational, and psychosocial factors. These resources can be useful for the cancer organization to develop a well-being blueprint: a detailed start plan with recognized strategies and interventions targeting all oncology stakeholders to support a culture of community in oncology.

scholarly journals Diagnosis and Management of Cirrhosis-Related Osteoporosis

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Lívia Alves Amaral Santos ◽  
Fernando Gomes Romeiro
Keyword(s):  
Quality Of Life ◽  
Risk Factors ◽  
Liver Transplantation ◽  
Primary Biliary Cirrhosis ◽  
Biliary Cirrhosis ◽  
Immunosuppressant Therapy ◽  
Treatment Of Osteoporosis ◽  
Screening Strategies ◽  
Cirrhotic Patients

Management of cirrhosis complications has greatly improved, increasing survival and quality of life of the patients. Despite that, some of these complications are still overlooked and scarcely treated, particularly those that are not related to the liver. This is the case of osteoporosis, the only cirrhosis complication that is not solved after liver transplantation, because bone loss often increases after immunosuppressant therapy. In this review, the definitions of bone conditions in cirrhotic patients are analyzed, focusing on the more common ones and on those that have the largest impact on this population. Risk factors, physiopathology, diagnosis, screening strategies, and treatment of osteoporosis in cirrhotic patients are discussed, presenting the more striking data on this issue. Therapies used for particular conditions, such as primary biliary cirrhosis and liver transplantation, are also presented.

Medical oncologists and quality of life of women treated for breast cancer.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 6051-6051
Author(s):  
C. R. Friese ◽  
T. M. Pini ◽  
P. Abrahamse ◽  
S. T. Hawley ◽  
S. J. Katz
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Medical Oncologists

Validity and utility of the University of Texas M. D. Anderson Symptom Inventory (MDASI) among prostate cancer patients: Data from E2Z02: Symptom Outcomes and Practice Patterns (SOAPP).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e15173-e15173
Author(s):  
Linda J. Patrick-Miller ◽  
Fengmin Zhao ◽  
Charles S. Cleeland ◽  
Lynne I. Wagner ◽  
Michael Fisch ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Medical Oncology ◽  
Performance Status ◽  
Eastern Cooperative Oncology Group ◽  
Symptom Assessment ◽  
Severe Nausea ◽  
Patient Reported

e15173 Background: Optimal treatment outcomes for patients (pts) with prostate cancer are dependent upon rigorous symptom assessment. The MDSAI, a patient-reported outcome measure of symptoms (sxs) and their impact validated in a sample of patients of diverse cancer types has the potential to inform symptom experience and guide treatment specific to prostate cancer pts. Methods: SOAPP, an Eastern Cooperative Oncology Group (ECOG) study, was conducted at academic and community medical oncology clinics and included pts with prostate cancer of all stages and phases of care. At baseline and 4 weeks, pts completed a measure of symptom severity and functional interference (MDASI). Symptom experiences and psychometric properties of the MDASI in prostate cancer pts (n = 320) were analyzed. Results: The 5 most prevalent moderate/severe sxs reported at baseline were fatigue (34%), disturbed sleep (25%), drowsiness (18%), pain (17%), and dry mouth (15%); moderate/severe nausea (5%) and vomiting (2%) were the least prevalent. At baseline ECOG performance status (PS) was ≥2 in 9% of pts. Pain, sadness, and difficulty remembering things occurred in 17%, 14%, and 13% respectively, and among pts whose PS worsened, severity of these sxs had the highest change scores at follow-up. Internal consistency and test-retest reliability of the MDASI were good, with Cronbach coefficient alphas ≥0.84 and intra-class correlations ≥0.78 for all subscales. Significantly higher scores and moderately large effects for the MDASI severity scale were reported by pts with poorer PS (2.2 vs 1.0, ES=.83) and tumor progression (2.4 vs 1.2, ES=.73) p<.05. Results were similar for the interference scale, demonstrating MDASI known-group validity. Pts whose quality of life declined showed significantly greater increase in severity (1.1 vs .14, p<.01) and interference (1.9 vs .28, p<.004) from baseline to follow-up than pts whose quality of life was unchanged, demonstrating MDASI sensitivity to change. Conclusions: The MDASI is a valid, reliable, and sensitive symptom assessment method for descriptive and clinical studies, and patient care in medical oncology outpatients with prostate cancer.

scholarly journals Treatment of spine metastases in cancer: a review

2019 ◽  
Vol 48 (4) ◽  
pp. 030006051988810
Author(s):  
Yu Chen ◽  
Yayi He ◽  
Chao Zhao ◽  
Xuefei Li ◽  
Caicun Zhou ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Life Expectancy ◽  
Cancer Patients ◽  
Integrated Approach ◽  
Spine Metastasis ◽  
Spine Metastases ◽  
Medical Oncologists ◽  
Diagnostic Technology ◽  
Pathological Development

As a consequence of the improvements in diagnostic technology along with gains in life expectancy of cancer patients, the incidence of spine metastases has increased. Spine metastases can affect the patient’s quality of life and negatively impact on their prognosis. Multidisciplinary treatments involve surgery, chemotherapy, radiosurgery and radiotherapy. Spine metastases should be treated using a multidisciplinary and integrated approach that involves spinal surgeons, medical oncologists and radiologists. More research is required to elucidate the pathological mechanisms involved in the aetiology of spine metastasis. This review describes the current situation regarding the diagnosis of spine metastasis, what is understood about the pathological development of spine metastasis and the evolution of the multidisciplinary treatments that are available for patients with spine metastases.

Sign in / Sign up

Export Citation Format

Share Document